The Evidence for Commercial House Dust Mite Immunotherapy Products: A pragmatic Systematic Review with Narrative Synthesis

Overview

Journal J Allergy Clin Immunol Glob

Specialty Allergy & Immunology

Date 2024 Aug 2

PMID 39092213

Authors

Timothy West

Constance H Katelaris

Affiliations

Soon will be listed here.

Abstract

House dust mite (HDM) allergen immunotherapy (AIT) has an established role in the treatment of perennial allergic rhinitis (AR) and allergic asthma (AA) triggered by HDM sensitization. We aimed to identify all double-blind, randomized, placebo-controlled trials of HDM AIT for the treatment of AR and AA in humans and to summarize the evidence for AIT products that are currently manufactured and available for clinical use. A total of 56 eligible double-blind, randomized, placebo-controlled trials of HDM AIT for the treatment of AA and/or AR in humans fit the inclusion criteria and investigated a total of 14 commercial AIT products; together, the 56 studies enrolled a total of 14,619 patients. Of the 56 studies, 39 studies investigated the current manufacturer-recommended maintenance dose (MRMD) of the product, and 17 investigated other doses. We identified 39 studies (12,539 patients randomized) for 8 sublingual immunotherapy (SLIT) products and 17 studies (2,080 patients randomized) for subcutaneous immunotherapy products. For AR, 3 products, the ALK 12 standardized-quality (SQ-HDM) SLIT tablet, the ALK 6 SQ-HDM tablet, and the SG 300 index of reactivity SLIT tablet, had both dose-finding studies (DFSs) and phase III definitive studies (DSs) to demonstrate efficacy of the MRMD of the product. For AA, 2 products, the ALK 12 SQ-HDM SLIT tablet and the ALK 6 SQ-HDM tablet, had both DFSs and DSs for the MRMD. No subcutaneous immunotherapy product had a paired DFS and DS supporting the MRMD. A total of 30 studies of products no longer commercially manufactured were excluded. This study will help to inform clinical care and product selection for the treatment of HDM-induced AR and AA.

Citing Articles

Optimization of Basophil Activation Test in the Diagnosis and Qualification for Allergen-Specific Immunotherapy in Children with Respiratory Allergy to the House Dust Mite .

Spiewak R, Gregorius A, Ostrowski G, Czarnobilska E Int J Mol Sci. 2024; 25(18).

PMID: 39337447 PMC: 11432158. DOI: 10.3390/ijms25189959.

References

Bonertz A, Tripathi A, Zimmer J, Reeb C, Kaul S, Bridgewater J . A regulator's view on AIT clinical trials in the United States and Europe: Why successful studies fail to support licensure. J Allergy Clin Immunol. 2022; 149(3):812-818. DOI: 10.1016/j.jaci.2022.01.004. View

Pakkasela J, Ilmarinen P, Honkamaki J, Tuomisto L, Andersen H, Piirila P . Age-specific incidence of allergic and non-allergic asthma. BMC Pulm Med. 2020; 20(1):9. PMC: 6954552. DOI: 10.1186/s12890-019-1040-2. View

Pfaar O, Gerth van Wijk R, Klimek L, Bousquet J, Creticos P . Clinical trials in allergen immunotherapy in the age group of children and adolescents: current concepts and future needs. Clin Transl Allergy. 2020; 10:11. PMC: 7181492. DOI: 10.1186/s13601-020-00314-1. View

Mahler V, Esch R, Kleine-Tebbe J, Lavery W, Plunkett G, Vieths S . Understanding differences in allergen immunotherapy products and practices in North America and Europe. J Allergy Clin Immunol. 2019; 143(3):813-828. DOI: 10.1016/j.jaci.2019.01.024. View

Bousquet J, Scheinmann P, Guinnepain M, PERRIN-FAYOLLE M, Sauvaget J, Tonnel A . Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy. 1999; 54(3):249-60. DOI: 10.1034/j.1398-9995.1999.00916.x. View

Wen Y, Zhou L, Li Y, Li Z, Deng W, Zhang T . Role of leptin in allergic rhinitis during sublingual immunotherapy. Eur Arch Otorhinolaryngol. 2018; 275(11):2733-2738. DOI: 10.1007/s00405-018-5123-0. View

Jutel M, Rudert M, Kreimendahl F, Kuna P . Efficacy and tolerability of a house dust mite allergoid in allergic bronchial asthma: a randomized dose-ranging trial. Immunotherapy. 2018; 10(13):1149-1161. DOI: 10.2217/imt-2018-0087. View

Huser C, Dieterich P, Singh J, Shah-Hosseini K, Allekotte S, Lehmacher W . A 12-week DBPC dose-finding study with sublingual monomeric allergoid tablets in house dust mite-allergic patients. Allergy. 2016; 72(1):77-84. PMC: 5217067. DOI: 10.1111/all.12913. View

Lue K, Lin Y, Sun H, Lu K, Hsieh J, Chou M . Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol. 2006; 17(6):408-15. DOI: 10.1111/j.1399-3038.2006.00443.x. View

10.

Nolte H, Maloney J, Nelson H, Bernstein D, Lu S, Li Z . Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. J Allergy Clin Immunol. 2015; 135(6):1494-501.e6. DOI: 10.1016/j.jaci.2014.12.1911. View

11.

Mortemousque B, Bertel F, De Casamayor J, VERIN P, Colin J . House-dust mite sublingual-swallow immunotherapy in perennial conjunctivitis: a double-blind, placebo-controlled study. Clin Exp Allergy. 2003; 33(4):464-9. DOI: 10.1046/j.1365-2222.2003.01622.x. View

12.

Bergmann K, Demoly P, Worm M, Fokkens W, Carrillo T, Tabar A . Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol. 2014; 133(6):1608-14.e6. DOI: 10.1016/j.jaci.2013.11.012. View

13.

Roberts G, Pfaar O, Akdis C, Ansotegui I, Durham S, Gerth van Wijk R . EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2017; 73(4):765-798. DOI: 10.1111/all.13317. View

14.

Xian M, Feng M, Dong Y, Wei N, Su Q, Li J . Changes in CD4+CD25+FoxP3+ Regulatory T Cells and Serum Cytokines in Sublingual and Subcutaneous Immunotherapy in Allergic Rhinitis with or without Asthma. Int Arch Allergy Immunol. 2019; 181(1):71-80. PMC: 6979435. DOI: 10.1159/000503143. View

15.

Bozek A, Kolodziejczyk K, Kozlowska R, Canonica G . Evidence of the efficacy and safety of house dust mite subcutaneous immunotherapy in elderly allergic rhinitis patients: a randomized, double-blind placebo-controlled trial. Clin Transl Allergy. 2017; 7:43. PMC: 5709914. DOI: 10.1186/s13601-017-0180-9. View

16.

Horn A, Bachert C, Brehmer D . [Clinical post-approval studies as part of the Therapy Allergen Regulation (TAV): A systematic review]. Z Evid Fortbild Qual Gesundhwes. 2021; 160:11-20. DOI: 10.1016/j.zefq.2020.11.010. View

17.

Aydogan M, Eifan A, Keles S, Akkoc T, Nursoy M, Bahceciler N . Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial. Respir Med. 2013; 107(9):1322-9. DOI: 10.1016/j.rmed.2013.06.021. View

18.

Demoly P, Emminger W, Rehm D, Backer V, Tommerup L, Kleine-Tebbe J . Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial. J Allergy Clin Immunol. 2015; 137(2):444-451.e8. DOI: 10.1016/j.jaci.2015.06.036. View

19.

Dhami S, Nurmatov U, Arasi S, Khan T, Asaria M, Zaman H . Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis. Allergy. 2017; 72(11):1597-1631. DOI: 10.1111/all.13201. View

20.

OHehir R, Gardner L, de Leon M, Hales B, Biondo M, Douglass J . House dust mite sublingual immunotherapy: the role for transforming growth factor-beta and functional regulatory T cells. Am J Respir Crit Care Med. 2009; 180(10):936-47. DOI: 10.1164/rccm.200905-0686OC. View